TW201739450A - Uses of poria cocos epidermis extract, poricoic acid A, and poricoic acid B in regulating blood glucose level - Google Patents

Abstract

Use of at least one of poricoic acid A and poricoic acid B in the manufacture of a medicament or a food product for regulating blood glucose level is provided, wherein at least one of poricoic acid A and poricoic acid B can be used in the form of a plant extract, and wherein the total amount of poricoic acid A and poricoic acid B in the plant extract is no less than 30 wt% based on the total weight of the plant extract. The food product could be a health food, a nutritional supplement food, or a special nutrition food.

Description

Use of suede extract, ruthenium acid A, and ruthenium acid B to regulate blood sugar

The present invention relates to the use of ecdysis extracts, poricoic acid A, and poricoic acid B, and more particularly to the use of serotonin.

Diabetes is a chronic metabolic disorder, and its main cause is that the mechanism of glucose uptake by cells in the body is abnormal, causing excessive glucose in the blood. In general, insulin secreted by the beta cells of the pancreas stimulates the uptake of glucose by fat cells and muscle cells, and has the effect of regulating blood sugar. When an organism suffers from insufficient insulin secretion or poor sensitivity to insulin due to factors such as obesity and aging, the blood glucose concentration will increase. Hyperglycemia may cause complications such as high blood pressure, heart disease, arteriosclerosis, and hyperlipidemia. In severe cases, sequelae such as blindness, impotence, amputation, and dialysis may occur.

At present, the clinical treatment of diabetes mainly includes exercise, diet control, and drug treatment, among which drug treatment includes insulin injection, oral hypoglycemic drugs, such as sufonylureas, biguanides, Alpha-glucosidase inhibitor Inhibitors, insulin sensitizer, and the like. However, with the change in human life patterns, the prevalence of diabetes has increased year by year. According to the prediction of the World Health Organization in 2008, it is estimated that the global diabetes population will exceed 300 million people by 2030. Therefore, the industry is still committed to developing drugs or methods with low side effects and effective blood sugar lowering.

The inventor of the present invention found that the extract of the molting and the poricoic acid A and poricoic acid B contained therein can effectively enhance the ability of cells to take up glucose, so it can be used for regulation. Blood sugar, in particular, provides excellent blood sugar lowering effects.

It is an object of the present invention to provide a use of at least one of ruthenium acid A and ruthenium acid B for the manufacture of a medicament or food product for use in regulating blood sugar. The dosage of the drug or food is about 0.05 mg/kg body weight to 1 mg/kg body weight per day based on the total weight of the brand new acid A and the brand new acid B, and the food may be a health food, a nutritional supplement or a special nutrient. food.

Preferably, at least one of ruthenium acid A and ruthenium acid B is used in the form of a plant extract. In the plant extract, the total content of the ruthenium acid A and the ruthenium acid B is not less than 30% by weight, preferably not less than 40% by weight based on the total weight of the plant extract. More preferably, at least one of ruthenium acid A and ruthenium acid B is used in the form of a suede extract. In the suede extract, pachymic acid, dehydropachymic acid, tumulosic acid, and dehydromoic acid are used as the total weight of the molting extract. Dehydrotumulosic acid) does not exceed 0.5% by weight, and dehydrotrametenolic acid, trametenolic acid, dehydroeburicoic acid, and lytic acid (eburicoic) Acid) The individual content does not exceed 5%. Preferably, in the suede extract, the respective contents of dehydroabietic acid, ceric acid, dehydroporosic acid, and porphyrin are all based on the total weight of the molting extract. Not more than 2.5%. More preferably, in the suede extract, the respective contents of dehydroabietic acid, oleic acid, dehydroporosic acid, and porphyrin are based on the total weight of the molting extract. No more than 1%.

Another object of the present invention is to provide a method of modulating blood glucose in a body comprising administering to an individual in need thereof an effective amount of at least one of ruthenium acid A and ruthenium acid B.

It is still another object of the present invention to provide a blood sugar regulating composition which is a pharmaceutical or food product and which comprises at least one of an effective amount of ruthenium acid A and ruthenium acid B.

Figure 1 shows the effect of the extract of the molting on the ability of mouse muscle cells to take up the glucose in the culture medium by the glucose oxidase assay; Figure 2 shows the glucose oxidase method. The results of the detection of the effect of the extract of the molting on the ability of the mouse adipocytes to take up the glucose in the culture solution; Figure 3A shows the glucose oxidase assay, the new acid A in the muscle cells of the mouse. The results of the influence of the ability; Figure 3B shows the effect of ruthenium acid B on the ability of mouse muscle cells to take up glucose in culture medium by glucose oxidase method; Figure 4A shows glucose oxidase method To test the effect of ruthenium acid A on the ability of mouse adipocytes to take up glucose in culture medium; Figure 4B shows the detection of ruthenium acid B by glucose oxidase method The result of the effect of mouse adipocytes on the uptake of glucose in the culture broth.

The invention will be described in detail below with reference to the embodiments of the present invention. The present invention may be practiced in various different forms without departing from the spirit and scope of the invention. . In addition, the terms "a", "an" and "the" and "the" Means the amount of a compound that effectively increases the ability of the individual's cells to take up glucose when administered to an individual; the term "individual" means a mammal, and the mammal may be a human or a non-human animal; the so-called "regulating blood sugar" Refers to the change of blood glucose concentration in the direction of normal value; the unit "mg / kg body weight" refers to the amount of drug required per kilogram of body weight.

The range of values used in the specification (for example, 5 to 100) is understood to include all rational numbers in the range and any range of rational numbers in the range. Therefore, the numerical range used in the present specification is Contains all possible combinations of values between the lowest and highest values listed. Further, when "about" is used herein before the numerical value, it substantially means that the difference is within 20%, preferably within 10%, and more preferably within 5%.

As explained above, the main cause of diabetes is that the mechanism of glucose uptake by cells in the living body is abnormal, and the glucose content in the blood is too high. The inventors of the present study have found that both ruthenium acid A and ruthenium acid B can increase the ability of cells to take up glucose, so they can be used to regulate blood sugar, especially to reduce excessive blood sugar. Accordingly, the present invention provides an application for regulating blood glucose using at least one of ruthenium acid A and ruthenium acid B, comprising using at least one of ruthenium acid A and ruthenium acid B to prepare one a method of regulating blood sugar by administering a drug or a food for regulating blood sugar, administering at least one of a new acid A and a new acid B to an individual in need thereof, and providing at least one of a new acid A and a new acid B Food or pharmaceutical composition.

The medicinal material refers to the dried sclerotium of the porcine fungus ( Poria cocos (Schw.) Wolf). The fungus is often parasitic on the roots of pine trees. The outer skin is light brown or dark brown (skin), and the interior is pink or white (clam meat). Traditional Chinese medicine records indicate that the clam meat department has sedative, diuretic, nutritional supplements, immunity and delay aging, while the molting is only used to treat skin edema.

As shown in the appended Examples, according to the present invention, a total amount of neodymidine A and ruthenic acid B can be obtained from the suede portion of not less than 30% by weight (based on the total weight of the molting extract). Extract. Therefore, at least one of the terpenic acid A and the ruthenium acid B used in accordance with the present invention can be used, for example, in the form of a plant extract of a hull extract, wherein in the plant extract used according to the present invention, The total content of ruthenium acid A and ruthenium acid B is not less than 30% by weight, preferably not less than 40% by weight, based on the total weight of the plant extract.

According to the present invention, the suede extract used may be an extract provided by the operation comprising the steps of: (a) extracting the suede portion with a first polar solvent to obtain a crude extract; (b) Drying the crude extract to obtain a crude extract powder; (c) extracting the crude extract powder with a second polar solvent to obtain a suede extract, wherein the first polar solvent and the second polar solvent are The same or different and each selected from the group consisting of water, ethanol, lye, acid, and combinations thereof. Wherein, the lye refers to any suitable alkaline solution having a pH greater than 7 (for example, a sodium hydroxide solution), and the acid solution refers to any suitable acidic solution having a pH of less than 7 (for example, a hydrochloric acid solution). In some embodiments of the present invention, the ethanol concentration is the same or not The same aqueous ethanol solution is used as the first polar solvent and the second polar solvent.

In the step (a), the ratio of the amount of the first polar solvent to the suede portion can be adjusted as needed. In general, the amount of the first polar solvent to be used is not particularly limited as long as the raw materials can be uniformly dispersed. For example, the volume ratio of the first polar solvent to the suede portion may be employed in step (a) from about 8:1 to about 16:1. In one embodiment of the present invention, the aqueous solution of ethanol is used as the first polar solvent, and the extraction of step (a) is carried out in a volume ratio of about 1:8.

In step (a), a suitable extraction time can be selected depending on the first polar solvent employed. For example, using an aqueous solution of ethanol as the first polar solvent and a volume ratio of the mashed portion: aqueous ethanol solution of 1:8, the extraction is usually carried out for at least 1 hour, preferably at least 2 hours, more preferably at least 3 hours. Further, other operations such as boiling, cooling, filtration, concentration under reduced pressure, resin column chromatography, and the like may be additionally performed to carry out the step (a). Alternatively, it may be necessary to pre-soak the suede in the first polar solvent for a period of time prior to performing step (a). For example, using an aqueous solution of ethanol as the first polar solvent, pre-soaking can be performed for about 12 hours.

In the step (c), the ratio of the amount of the second polar solvent to the crude extract powder obtained in the step (b) may be adjusted as needed. In general, the amount of the second polar solvent to be used is not particularly limited as long as the coarse extract powder can be uniformly dispersed. For example, the volume ratio of the second polar solvent to the mash crude extract powder may be employed in step (c) from about 8:1 to about 16:1. In one embodiment of the present invention, the extraction of the step (c) is carried out by using an aqueous solution of ethanol as the second polar solvent and a crude extract of the molting portion of the pulp: an aqueous solution of ethanol in a volume ratio of about 1:8.

The rind extract used in accordance with the present invention may also be a dry product which is provided by drying the extract obtained in step (c). for Maximize the extraction benefit, if necessary, repeat the extraction of the suede with the same or different first polar solvent before step (b), and combine the extracts from the multiple extractions to provide The crude extract of step (b) is carried out; the cycles of step (b), step (c), and other operations as desired may also be repeated.

In the suede extract used according to the present invention, the total content of the ruthenium acid A and the ruthenium acid B is not less than 30% by weight, preferably not less than 40% by weight based on the total weight of the suede extract. %, and the respective contents of decanoic acid, dehydroabietic acid, toluic acid, and dehydromomoic acid are not more than 0.5%, dehydroabietic acid, ceric acid, dehydrogenated porphyric acid, layer bacteria The individual content of the acid does not exceed 5%. Preferably, in the suede extract, the respective contents of dehydroabietic acid, ceric acid, dehydroporosic acid, and porphyrin are all based on the total weight of the molting extract. Not more than 2.5%. More preferably, in the suede extract, the respective contents of dehydroabietic acid, oleic acid, dehydroporosic acid, and porphyrin are based on the total weight of the molting extract. No more than 1%.

The pharmaceutical composition or drug system provided in accordance with the application of the present invention may be in any convenient form, without particular limitation, and may be in a suitable dosage form depending on the intended use. By way of example, but not by way of limitation, the pharmaceutical composition or medicament may be administered orally or non-orally (eg, subcutaneous, intravenous, intramuscular, or intraperitoneal) to an individual in need thereof. Wherein, depending on the form of use and use, a suitable carrier may be selected to provide the pharmaceutical composition or medicament, wherein the carrier comprises an excipient, a diluent, an adjuvant, a stabilizer, an absorption delaying agent, a disintegrating agent. , solubilizers, emulsifiers, antioxidants, binders, binders, tackifiers, dispersants, suspending agents, lubricants, moisture absorbers, etc.

Taking a dosage form suitable for oral administration as an example, in the application according to the present invention The pharmaceutical composition or drug system can contain any pharmaceutically acceptable carrier which does not adversely affect the desired benefit of the active ingredient (i.e., ruthenium A, ruthenium B, or ecdy extract). For example: water, saline, dextrose, glycerol, ethanol or the like, cellulose, starch, sugar bentonite, and combinations of the foregoing. The pharmaceutical composition or medicament may be provided in a dosage form suitable for oral administration by any convenient method, for example, a tablet (for example, a dragee), a pill, a capsule, a granule, a powder, a flow extract, a solution, a syrup , suspensions, tinctures, etc.

As for injections or drips suitable for subcutaneous, intravenous, intramuscular, or intraperitoneal injection, one or more, for example, isotonic solutions, salt buffers, may be included in the pharmaceutical compositions or medicaments provided in accordance with the use of the present invention ( Ingredients such as phosphate buffer or citrate buffer, solubilizer, emulsifier, 5% sugar solution, and other carriers, intravenous infusion, emulsion intravenous infusion, dry powder injection, suspension injection, or dry powder A pharmaceutical composition or a drug is provided in a dosage form such as a suspension injection. Alternatively, the pharmaceutical composition or medicament can be prepared as a pre-injection solid, the pre-injection solid is provided in a dosage form, or emulsifiable, which is soluble in other solutions or suspensions, and administered prior to administration to an individual in need thereof The solid before injection is dissolved in other solutions or suspensions or emulsified to provide the desired injection.

Optionally, a pharmaceutical composition or a medicament provided according to the application of the present invention may further contain a suitable amount of an additive, for example, a flavoring agent which enhances the mouthfeel and visual sensation of the pharmaceutical composition or medicament when administered, Toners, colorants, etc., as well as buffers, preservatives, and agents that improve the stability and storage of the drug. Preservatives, antibacterial agents, antifungal agents, etc. In addition, the pharmaceutical composition or medicament may optionally contain one or more other active ingredients (eg, an antioxidant, an insulin sensitizer, etc.) or may be used in combination with a drug containing the one or more other active ingredients to further enhance the pharmaceutical combination. The efficacy of the substance or drug or the flexibility and formulation of the formulation of the formulation, as long as the other active ingredient is not detrimental to the benefits of the active ingredient of the present invention (ie, ruthenium A, ruthenium B, or ecdy extract) The impact can be.

The pharmaceutical composition or drug system provided in accordance with the application of the present invention can be administered at different administration times, such as once a day, multiple times a day, or several times a day, depending on the needs, age, weight, and health of the individual. It varies. For example, when administered orally to a body to regulate blood sugar, the amount is from about 0.01 mg/kg body weight to 5 mg/kg body weight per day based on the total weight of the brand new acid A and the brand new acid B. Preferably, it is from about 0.03 mg/kg body weight to 2 mg/kg body weight per day, more preferably from about 0.05 mg/kg body weight to 1 mg/kg body weight per day. Alternatively, in an amount of from about 0.025 mg/kg body weight to 25 mg/kg body weight per day, preferably from about 0.075 mg/kg body weight to 10 mg/kg body weight per day, more preferably about 0.125 per day. From mg/kg to 5 mg/kg.

The food provided according to the application of the present invention may be a health food, a nutritional supplement or a special nutritious food, and may be made into, for example, dairy products, processed meat products, breads, noodles, biscuits, buns, capsules, juices. , tea, sports drinks, nutritional drinks and other products, but not limited to this. Preferably, the food product according to the application of the present invention is provided in the form of a health food.

The health food, nutritional supplement food and special nutritious food provided by the application according to the present invention can be eaten at different frequencies once a day, once a day, or several times a day, depending on the age, weight, and The recommended intake varies depending on the health status. The content of the brand new acid A, the brand new acid B, or the skin extract of the health food, the nutritional supplement food and the special nutritious food provided by the invention may also be adjusted for a specific ethnic group, preferably adjusted to be taken daily. The amount. For example, based on the total weight of ruthenium acid A and ruthenium acid B, if the recommended intake of a body is about 70 mg of ruthenium acid A and ruthenium acid B per day, the health food product Each serving contains a total of 35 mg of ruthenium acid A and ruthenium acid B, and the individual can consume about two servings of the health food per day.

The recommended use amount, the use standard and conditions of a specific ethnic group (such as pregnant women, diabetic patients, kidney patients), or other foods or medicines may be packaged in addition to the health food, nutritional supplement food and/or special nutritious food of the present invention. The recommended recommendations for taking the user can be taken at home without the guidance of a physician, pharmacist or related deacon without any safety concerns.

The invention also provides a method of modulating blood glucose comprising administering to an individual in need thereof an effective amount of an active ingredient, wherein the active ingredient is at least one of ruthenium A and ruthenium B. In the method of regulating blood sugar according to the present invention, the aspect of the active ingredient, the administration route, the administration form, the applicable dose, and the application of the related treatment are as described above.

The invention is further illustrated by the following examples. The embodiments are provided by way of illustration only and are not intended to limit the scope of the invention. This hair The scope of protection is as shown in the attached patent application.

Example [Preparation Example]

A. Preparation of mink extract

A-1. Take the medicinal herbs (source origin is Yunnan), peel off the outer skin after washing (hereinafter referred to as "skin"), and the rest is the meat department (hereinafter referred to as "the meat department"). The above-mentioned suede portion was taken up in a 75% ethanol aqueous solution at a volume ratio of 1:8 (medicinal material: aqueous ethanol solution) at room temperature for 12 hours, then boiled and extracted (for 3 hours). The aforementioned extraction steps were repeated for a total of three times. The resulting extract was combined three times and filtered to remove insolubles to obtain a crude extract. Next, the crude extract described above was concentrated under reduced pressure to remove the solvent, and then dried by a spray dryer to obtain a crude extract powder.

A-2. The crude extract powder obtained by taking A-1 is mixed with 95% ethanol in a volume ratio of 1:8 (crude extract powder: aqueous ethanol solution), and extracted (for 3 hours), and then, Separation was carried out using a column in which the tannin was used as a stationary phase to obtain a suede extract.

A-3. The crude extract powder obtained by taking A-1 was uniformly dispersed in pure water in a volume ratio of 1:10 (crude extract powder: water). Next, sodium hydroxide was added to raise the pH of the mixture to about 12, and then poured into a brewing tank maintained at a temperature of 65 ° C and uniformly stirred until the reaction was completed. Then, the mixture was neutralized with 12 N concentrated hydrochloric acid, and the filtrate was removed by centrifugation, and the remaining insoluble matter was washed with pure water, and the insoluble matter was dried by a spray dryer to obtain an extract powder. The above extract powder was extracted three times with a 1N aqueous solution of sodium hydrogencarbonate in a volume ratio of 1:20 (extract powder: 1N aqueous solution of sodium hydrogencarbonate), and the extract obtained by three times extraction was carried out with 12 N concentrated hydrochloric acid. And, after centrifugation, the filtrate was removed, and the remaining insoluble matter was washed with pure water, and the insoluble matter was dried by a spray dryer to obtain a suede extract.

A-4. The components of the extract obtained by A-2 and A-3 were detected by liquid chromatography/ultraviolet/mass spectrometry at 243 nm and 210 nm, respectively, and subjected to high performance liquid chromatography. The content of each component in each of the extracts was quantified, and the analysis results of the extracts obtained from A-2 are shown in Table 1, and the results of the analysis of the extracts obtained in Tables A-3 are shown in Table 2.

As can be seen from Table 1, the molting extract obtained by A-2 contains a high amount of ruthenium acid A (32.72% by weight of the extract) and ruthenium acid B (the weight percentage of the extract is 10.44%), low amount of dehydroabietic acid, ceric acid, dehydroporosporin and streptococcus (2.01%, 0.85%, 1.2%, 0.83% by weight of the extract, respectively), And a very low amount of dehydromoic acid (0.46% by weight of the extract), but does not contain tannic acid, dehydroabietic acid and toluic acid.

As can be seen from Table 2, the molting extract obtained by A-3 contains a high amount of ruthenium acid A (41.06% by weight of the extract) and ruthenium acid B (the weight percentage of the extract is 16.50). %), low amounts of porcine acid C, dehydroabietic acid (1.15%, 0.58% by weight of the extract, respectively), and very low amounts of dehydrohydroauric acid, 3-epoxy-dehydrogenated soil Molybdic acid, ceric acid, dehydroporosporin and porphyrin (0.31%, 0.40%, 0.35%, 0.19%, 0.20% by weight of the extract, respectively), but without citric acid, go Hydroquinone and toluic acid.

B. Preparation of ruthenium acid A and ruthenium acid B

B-1. The molting extract obtained by A-2 or A-3 was uniformly dissolved in methanol at a volume ratio of 1:500 (skin extract: methanol). After insoluble matter was removed by filtration, a preparative high-performance liquid chromatograph (mixed with methanol and water as a mobile phase) was used to separate and collect the neomycin A and the ruthenium B at a wavelength of 243 nm. After that, the methanol was removed by a vacuum condenser to obtain ruthenium acid A and ruthenium acid B, respectively.

B-2. The new acid A and the ruthenium acid B obtained by B-1 were detected by liquid chromatography/ultraviolet/mass spectrometry at 243 nm, respectively, and the results showed that ruthenium acid A and ruthenium acid were obtained. The purity of B is greater than 98%.

C. Cell culture

Differentiated mouse muscle cells (C2C12, purchased from ATCC) and adipocytes (3T3-L1, purchased from ATCC) were cultured in Duss containing 2% bovine serum albumin (BSA) but not serum-free. The medium was modified in Dulbecco's modified Eagle's medium (DMEM) for 16 hours. Next, it was washed with Dulbecco's phosphate-buffered saline (D-PBS), and the medium was changed to 0.2% BSA-DMEM medium containing 500 μg/ml of glucose for use in subsequent experiments.

Example 1: Effect of extract of ecdysone on the ability of cells to take up glucose

(1-1) Muscle cells

The C2C12 cells provided in [Preparation Example] were divided into five groups and cultured in the following medium for 2 hours: 1. Group I: BSA-DMEM medium containing 500 μg glucose/ml; 2. Group II: BSA-DMEM medium containing 500 micrograms of glucose per milliliter and insulin at a concentration of 100 nanomolar; 3. Group III: containing 500 micrograms of glucose per milliliter, and a concentration of 0.1 micrograms per milliliter. [Preparation Example A-2] BSA-DMEM medium of the rind extract solution provided; 4. Group IV: containing 500 μg of glucose/ml, and a concentration of 1 μg/ml [Preparation Example A- 2] BSA-DMEM medium of the fur extract solution provided; 5. Group V: containing 500 μg of glucose/ml, and a concentration of 10 μg/ml [Preparation Example A-2] BSA-DMEM medium for the skin extract solution.

Thereafter, the glucose content in each group of cell culture fluids was measured by the glucose oxidase method to understand the degree of glucose consumption of each group (representing the ability of cells to take up glucose). Finally, the relative glucose uptake ability of the other groups was calculated based on the results of the control group (i.e., the cells cultured in the first group culture solution), and the results are shown in Fig. 1.

As can be seen from Fig. 1, the glucose uptake ability of the cells treated with the extract of the molting portion of the present invention (i.e., cells cultured in the culture medium of Group III, IV, or V) is significantly improved or even exceeded compared to the control group. Positive control group (ie, cells cultured in Group II culture medium). The foregoing results show that the extract of the suede of the present invention can effectively increase the ability of muscle cells to take up glucose, and thus can be used for regulating blood sugar.

(1-2) fat cells

The 3T3-L1 cells provided in [Preparation Example] were divided into five groups and cultured in the medium groups I to V described in Example 1 (1-1), respectively. hour. Next, the glucose content in each group of cell culture fluids was measured by the glucose oxidase method to understand the degree of glucose consumption of each group (representing the ability of cells to take up glucose). Finally, the relative glucose uptake ability of the other groups was calculated based on the results of the control group (i.e., the cells cultured in the first group culture solution), and the results are shown in Fig. 2.

As can be seen from Fig. 2, the glucose uptake ability of the cells treated with the extract of the suede extract of the present invention (i.e., the cells cultured in the culture medium of Group III, IV, or V) has an increasing tendency compared with the control group. Among them, the upward trend of the high dose group (cell cultured in the group V culture medium) was the most significant. The foregoing results show that the extract of the suede of the present invention can effectively enhance the ability of fat cells to take up glucose, and thus can be used to regulate blood sugar.

Example 2: Effect of ruthenium acid A and ruthenium acid B on glucose uptake by cells

(2-1) Muscle cells

The C2C12 cells provided in [Preparation Example] were divided into eight groups and cultured in the following medium for 2 hours: 1. Group i: BSA-DMEM medium containing 500 μg glucose/ml; Group ii: BSA-DMEM medium containing 500 μg glucose/ml and insulin at a concentration of 100 nanomolar; 3. Group iii: containing 500 μg glucose/ml, and a concentration of 0.1 μg/ml [Preparation implementation] Example B-1] BSA-DMEM medium of ruthenium acid A or ruthenium acid B provided; 4. Group iv: containing 500 μg glucose/ml, and a concentration of 1 μg/ml [Preparation Example B- 1] BSA-DMEM medium provided with neomycin A (or ruthenic acid B); 5. Group v: BSA-DMEM medium containing 500 μg/ml of glucose and a new acid A (or ruthenic acid B) supplied in [Preparation Example B-1] at a concentration of 10 μg/ml.

Next, the glucose oxidase method was used to determine the glucose content in each group of cell culture fluids to understand the degree of glucose consumption of each group (representing the ability of cells to take up glucose), and finally, to control the group (ie, to culture in the i-th culture medium) Based on the results of the cells, the relative glucose uptake ability of the other groups was calculated, and the results are shown in Fig. 3A and Fig. 3B. Wherein, the 3A map comprises a control group, a positive control group (ie, cells cultured in the ii group culture medium), and a group treated with ruthenium acid A (ie, cultured in the group iii, iv, or v) A liquid cultured cell in which the culture solution contains the result of ruthenium acid A). Figure 3B includes a control group, a positive control group, and a group treated with ruthenium acid B (i.e., cells cultured in a culture medium of Group iii, iv, or v, wherein the culture solution contains ruthenium B )the result of.

As can be seen from Fig. 3A, the glucose uptake capacity of the group treated with ruthenium acid A was significantly increased to be comparable to that of the positive control group compared to the control group. The foregoing results show that ruthenium acid A can effectively increase the ability of muscle cells to take up glucose, so it can be used to regulate blood sugar.

As can be seen from Figure 3B, the glucose uptake capacity of the group treated with ruthenium B was also significantly improved compared to the control group. The foregoing results show that ruthenium B can also regulate blood sugar by increasing the ability of muscle cells to take up glucose.

(2-2) fat cells

3T3-L1 cells supplied in [Preparation Example] were taken, divided into eight groups and cultured in the i- to v-group medium described in Example 2 (2-1) for 2 hours. Next, the grapes in each group of cell culture fluids were determined by the glucose oxidase method. Sugar content to understand the extent of glucose consumption in each group (representing the ability of cells to take up glucose). Finally, the relative glucose uptake ability of the other groups was calculated based on the results of the control group (i.e., the cells cultured in the i-th culture medium), and the results are shown in Fig. 4A and Fig. 4B. Wherein, the 4A map comprises a control group, a positive control group (ie, cells cultured in the ii group culture medium), and a group treated with ruthenium acid A (ie, cultured in the group iii, iv, or v) A liquid cultured cell in which the culture solution contains the result of ruthenium acid A). Figure 4B includes a control group, a positive control group, and a group treated with ruthenium acid B (i.e., cells cultured in a culture medium of Group iii, iv, or v, wherein the culture solution contains ruthenium B )the result of.

As can be seen from Fig. 4A, the glucose uptake capacity of the group treated with ruthenium acid A has an increasing tendency compared with the control group, wherein the middle dose group (i.e., the cells cultured in the iv group) The upward trend of the high-dose group (i.e., the cells cultured in the v-th culture medium) was remarkable. The foregoing results show that ruthenium acid A can effectively increase the ability of fat cells to take up glucose, so it can be used to regulate blood sugar.

As can be seen from Fig. 4B, the glucose uptake capacity of the group treated with ruthenium B was significantly higher than that of the control group. The foregoing results show that ruthenium B can also regulate blood sugar by increasing the ability of fat cells to take up glucose.

As shown in the above examples, the extract of the suede of the present invention, and the ruthenium acid A and the ruthenium acid B can enhance the ability of the living body to take up blood sugar, can be used to regulate blood sugar, and in particular can reduce excessive blood sugar. .

Claims (13)

A use of at least one of poricoic acid A and poricoic acid B for the manufacture of a medicament or food for regulating blood sugar. The use of claim 1, wherein at least one of ruthenium acid A and ruthenium acid B is used in the form of a plant extract. The use of claim 2, wherein the total content of ruthenium acid A and ruthenium acid B is not less than 30% by weight based on the total weight of the plant extract. The use of claim 3, wherein the total content of ruthenium acid A and ruthenium acid B is not less than 40% by weight based on the total weight of the plant extract. The use of any one of claims 2 to 4, wherein the plant extract is a mink extract. The use of claim 5, wherein pachymic acid, dehydropachymic acid, tumulosic acid, and dehydromoic acid are based on the total weight of the molting extract. The respective content of dehydrotumulosic acid) does not exceed 0.5%. The use of claim 5, wherein dehydrotrametenolic acid, trametenolic acid, dehydroeburicoic acid, lamellar pores are based on the total weight of the molting extract The individual content of eburicoic acid does not exceed 5%. The use of claim 7, wherein the respective contents of dehydroabietic acid, ceric acid, dehydroporosic acid, and porphyrin are not more than 2.5% based on the total weight of the rind extract. The use of claim 8, wherein the respective contents of dehydrocarotic acid, ceric acid, dehydroporosic acid, and porphyrin are not more than 1% based on the total weight of the rind extract. The use of claim 5, wherein the suede extract is provided by the operation comprising: (a) extracting a suede portion with a first solvent to obtain a crude extract; and (b) drying the crude extract. Obtaining a crude extract powder; (c) extracting the crude extract powder with a second solvent to obtain a rind extract, wherein the first solvent is the same as or different from the second solvent It is selected from the group consisting of water, ethanol, lye, acid, and combinations thereof. The use of claim 10, wherein the first solvent and the second solvent are ethanol solutions having the same or different ethanol concentration. The use of claim 1, wherein the amount of the drug or food is from about 0.05 mg/kg body weight to 1 mg/kg body weight per day based on the total weight of the brand new acid A and the brand new acid B. The use of claim 1, wherein the food is a health food, a nutritional supplement or a special nutritious food.